Visualitzant O - Articles científics per títol

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

Iranzo Gómez, Patricia; Pardo Aranda, Nuria; Callejo Perez, Ana; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Soleda, Mireia; Jiménez Flores, José Antonio; Hernandez Losa, Javier; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Carbonell, Caterina; Frigola Rissech, Joan (BMJ, 2022-04)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07)

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Koessler, Thibaud; Alsina Maqueda, Maria; Arnold, Dirk; Ben-Aharon, Irit; Lutz, Manfred; Obermannova, Radka (Springer Nature, 2021-09)

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

Villanueva Cardús, Josep; Bellio, Chiara (AME Publishing Company, 2020-07)

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Pujals-Pruneda, Mireia; Resar, Linda; Villanueva Cardús, Josep (MDPI, 2021-09-09)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Yndestad, Synnøve; Engebrethsen, Christina; Nikolaienko, Oleksii; Vintermyr, Olav Karsten ; Lillestøl, Reidun; Llop-Guevara, Alba; Herencia Ropero, Andrea; Serra, Violeta (American Society of Clinical Oncology, 2023-12-01)

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Pellegrino, B.; Musolino, Antonio; Llop Guevara, Alba; Serra Elizalde, Violeta; De Silva, P.; Hlavata, Z. (Elsevier, 2020-02-01)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Serra Camprubi, Queralt; Verdaguer Mata, Helena; Oliveros, Winona; Lupión-Garcia, Núria; Llop Guevara, Alba; Molina, Cristina; Vila Casadesus, Maria; Querol Paños, Jessica; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Serra Elizalde, Violeta; Arribas López, Joaquin Vicente; Tabernero Caturla, Josep; Peiro Sales, Sandra; Macarulla Mercadé, Teresa; Tian, Tian V; Bernadó Morales, Cristina; Arenas Lahuerta, Enrique Javier; Frigola Rissech, Joan; Fabregat Franco, Carles; Castet, Florian; Miquel Aymar, Josep Maria; Escudero Iriarte, Carmen; Yáñez, Mariana; Escorihuela Baez, Marta (American Association for Cancer Research, 2023-01-17)

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Alpuim Costa, Diogo; Nobre, José Guilherme; Vaz Batista, Marta; Ribeiro, Catarina; Calle, Catarina; Cortés, A.; Cortés Castan, Javier (Frontiers Media, 2021-02)

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ramos, Javier; Vega, Juan Francisco; Cruz, Victor; Sanchez-Sanchez, Eduardo; Cortés Castan, Javier; Martinez-Salazar, Javier (MDPI, 2019-03-01)

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Tempero, Margaret A.; Tabernero Caturla, Josep; Reni, Michele; Van Cutsem, Eric; Hendifar, Andrew E.; Macarulla Mercadé, Teresa; Oh, Do-Youn (Elsevier, 2021-05)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Giné Soca, Eva; de la Cruz, Fatima; Jimenez-Ubieto, Ana; Terol, M. Jose; Marin Niebla, Ana; Martín García-Sancho, Alejandro; Lopez-Jimenez, Javier (American Society of Clinical Oncology, 2022-04-10)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Serra Elizalde, Violeta; Wang, Anderson T.; Castroviejo Bermejo, Marta; Polanska, Urszula M.; Palafox Sánchez, Marta; Llop Guevara, Alba; Guzman Torres, Marta; Rodriguez Ferreiro, Olga; Grueso Gragera, Judit; Arribas López, Joaquin Vicente; Cortés Castan, Javier; Cruz Zambrano, Cristina; Balmaña Gelpí, Judith; Saura Manich, Cristina; Herencia Ropero, Andrea (American Association for Cancer Research, 2022-10-15)

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Tian, Tian V; Vidal, Enrique; Graf, Thomas; Stik, Grégoire (MyJove Corporation, 2020-04-29)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Jiménez-Labaig, P.; Pacheco-Barcia, V.; Cebrià, A.; Gálvez, F.; Obispo, B.; Páez, David; Felip Font, Enriqueta; Elez Fernandez, Mª Elena; Bosch-Barrera, Joaquim (Elsevier, 2021-08)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Blumenberg, Viktoria; Iacoboni García-Calvo, Gloria; Kharboutli, Soraya; Hernani, Rafael; Barba Suñol, Pere; Lopez Corral, Lucia; Rejeski, Kai (Wolters Kluwer Health, 2023-04)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Lheureux, Stephanie; Prokopec, Stephenie; Oldfield, Leslie E.; Gonzalez-Ochoa, Eduardo; Bruce, Jeff; Wong, Derek; OAKNIN, ANA (American Association for Cancer Research, 2023-09-15)

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Ernst, Matthew; Yuasa, Takeshi; Takemura, Kosuke; Suárez Rodríguez, Cristina; Navani, Vishal; Wells, Connor; Donskov, Frede (American Medical Association, 2022-06-01)

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Rubio Pérez, Carlota; Planas Rigol, Ester; Trincado, Juan L.; Bonfill Teixidor, Ester; Arias Piñeiro, Alexandra; Marchese, Domenica; Iurlaro, Raffaella; Martínez Ricarte, Francisco Ramón; Escudero Monreal, Laura; Cordero Asanza, Esteban Xavier; Cicuendez López Ocaña, Marta; Nuciforo, Paolo Giovanni; Sahuquillo Barris, Joan; Tabernero Caturla, Josep; Seoane Suarez, Joan; Serna, Garazi (Nature Research, 2021-03-08)

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Cortellini, Alessio; Dettorre, Gino M; Dafni, U.; Aguilar Company, Juan; Castelo-Branco, L.; Lambertini, Matteo (BMJ, 2022-11)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC ﻿

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer ﻿

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group ﻿

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer ﻿

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! ﻿

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer ﻿

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review ﻿

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation ﻿

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine ﻿

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations ﻿

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study ﻿

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial ﻿

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance ﻿

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C) ﻿

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM) ﻿

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL ﻿

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression ﻿

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma ﻿

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment ﻿

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries